Cargando…
Emicizumab in acquired haemophilia A: about two clinical cases and literature review
Acquired haemophilia A (AHA) is a rare and severe haemorrhagic autoimmune disease caused by autoantibodies directed against factor VIII (FVIII). Treatment is based on two principles, including haemostatic control to compensate FVIII inhibition and eradication of inhibiting antibodies using immunosup...
Autores principales: | Hansenne, Amandine, Hermans, Cedric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404634/ https://www.ncbi.nlm.nih.gov/pubmed/34471508 http://dx.doi.org/10.1177/20406207211038193 |
Ejemplares similares
-
Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A
por: Al-Banaa, Kadhim, et al.
Publicado: (2021) -
Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021) -
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019) -
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022) -
Management of acquired haemophilia A in severe Covid‐19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis
por: Gelbenegger, Georg, et al.
Publicado: (2022)